Greenwich LifeSciences announced a delay in filing its Form 10-K for the fiscal year ending December 31, 2025, due to ongoing audit finalizations focused on accounts payable related to its global Phase III breast cancer trial, FLAMINGO-01. The company expects to complete the audit and file the report by the end of May alongside its Form 10-Q for Q1 2026. The FLAMINGO-01 trial, testing the immunotherapy GLSI-100, shows promising preliminary results with a 70-80% reduction in breast cancer recurrence in one patient arm. The company reported an unaudited cash balance of approximately $10.5 million as of March 31, 2026, supporting continued trial progress and operations.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
